
ONCOLOGY INSTITUTE INC/THE
TOINASDAQTrading Snapshot
- Day Range
- $5.09 β $5.22
- 52-Week Range
- $2.32 β $7.05
- Volume
- $3.59B
- Avg Volume
- $4.76B
- Shares Outstanding
- 100.0M
- Next Earnings
- Sep 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $503M
- Last Q Revenue
- $161M
- P/E Ratio
- β
- P/S Ratio
- 0.9x
- EPS (TTM)
- $-0.45
- Dividend Yield
- β
Why Investors Own TOI
- βHigh-growth profile β revenue up +25.4% YoY with expanding US Equity exposure.
- βHealthy economics β 34% gross margin and 4% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ONCOLOGY INSTITUTE INC/THE
The Oncology Institute (TOI) is a specialized healthcare provider delivering a full range of medical oncology services throughout the United States. Its comprehensive offerings include direct physician care, integrated on-site infusion and medication dispensing facilities, and advanced clinical trial management. The institute also provides radiation therapy, specialized outpatient programs for stem cell transplants and transfusions, and robust patient support services. Furthermore, TOI is actively involved in operating palliative care initiatives and overseeing clinical trials. These services are specifically designed to meet the needs of adult and senior cancer patients. The company maintains a significant operational footprint with 67 clinic locations. The Oncology Institute was established in 2007 and is headquartered in Cerritos, California.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
ONCOLOGY INSTITUTE INC/THE tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift TOI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ONCOLOGY INSTITUTE INC/THE announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.